• E protein was studied using specific anti E antibodies in

  2019-07-15

  

  E1 protein was studied using specific anti-E1 Ethacrynic Acid in wild type cells and in transfected cells overexpressing the enzyme. The results revealed several unusual characteristics, which are unique to this ubiquitin-activating enzyme. The E1 was translated as a full-length protein and then qu

• Herein we designed a strategy utilizing the target protectio

  2019-07-15

  

  Herein, we designed a strategy utilizing the target-protection method to produce a signal in a system involving fluorescence CuNPs stabilized by dumbbell template DNA (DT DNA) through a locked circle consisting of two poly T loops and a poly (ATTA) stem. In the presence of MTase, DT DNA was modified

• A surprising second functional effect was found in culture

  2019-07-15

  

  A surprising second functional effect was found in culture experiments. Inclusion of LTD4 reduced the frequency of Fas receptor (CD95) expression. Once again, this effect, although modest, was reversed by a cysLT1 receptor antagonist. The biologic significance of this effect or its mechanism remaine

• Steady state mRNA levels of CYP

  2019-07-15

  

  Steady-state mRNA levels of CYP3A isoforms were not changed during liver insufficiency. Suppression of these isoforms was observed only at the protein and activity levels, suggesting a nongenomic mechanism of CYP3A isoform downregulation during liver insufficiency. Nonetheless, transcriptional activ

• br Material and methods br Results

  2019-07-15

  

  Material and methods Results Discussion In vitro evidence indicates that LAS191859 is a potent CRTh2 antagonist as demonstrated in GTPγS binding studies with potency in the low nanomolar range and in addition it demonstrates a long receptor residence time. This potency is also maintained in

• Treatment related adverse events have been

  2019-07-15

  

  Treatment-related adverse events have been a serious issue in clinical application. Severe toxicity has been reported in clinical trials using antibody blockade of CSF-1R (20 mg/kg), PD-1, and CTLA-4.29, 30, 31 However, apparent side effects were not observed in our study with PLX3397 treatment alon

• In addition to carbamates organophosphates are classic inhib

  2019-07-15

  

  In addition to carbamates, organophosphates are classic inhibitors of cholinesterases. Previous studies with aquatic organisms have demonstrated their sensitivity to such chemicals. For example, individuals of the freshwater fish Colossoma macropomum exposed to the organophosphate dichlorvos, chlorp

• br Results and Discussion br Conclusion What we have

  2019-07-15

  

  Results and Discussion Conclusion What we have shown here is that highly specific antagonist can be a very useful tool, can mimic gene KO experiments or even further dissect receptor function. We just took ETA antagonist as an example and found that ETA mediates physiological closure of DA wh

• A putative SHBG receptor SHBG R has

  2019-07-15

  

  A putative SHBG Tranilast (SHBG-R) has been postulated for about thirty years [66], [69], [70]. The characterization of this receptor has been researched by several groups. There are different ideas on how this receptor works. On the one hand Fortunati et al. provide evidence that SHBG is already b

• Given the potency enhancing effect of the butyl group

  2019-07-15

  

  Given the potency enhancing effect of the 4--butyl group, this substitution was incorporated into the Eastern portion of the molecule for further SAR investigations (). Removal of the phenol group (SR19822) or moving it from the -position to the -position (SR19552) or led to significant loss of acti

• br Activatable MRI probes MRI is

  2019-07-15

  

  Activatable MRI probes MRI is commonly used in clinics around the world and has the advantages of outstanding tissue-penetration depth and extremely high spatial resolution for in vivo imaging [33]. MRI has relatively poor sensitivity and usually requires Eltrombopag Olamine agents to enhance th

• ELUXA HM EMSI is an ongoing pivotal Phase II

  2019-07-15

  

  ELUXA 1 (HM-EMSI-202) is an ongoing pivotal Phase II global clinical trial, designed to further investigate the efficacy and safety of Olmutinib in patients T790M-positive NSCLC with acquired resistance after first-line EGFR TKIs. Primary endpoint is ORR according to RECIST 1.1, while secondary endp

• The strand domain swap in

  2019-07-15

  

  The β strand domain swap in the UbV.XR dimer appears to be a unique arrangement for a Ub-based dimer. In solution, free Ub has a KD of ∼5 mM for the monomer-dimer equilibrium, and the two subunits in the dimer adopt a range of relative orientations involving residues from Ub’s β sheet (Liu et al., 2

• AMG-458 We initially identified four putative Egr binding

  2019-07-15

  

  We initially identified four putative Egr1 AMG-458 (−39/−36, −105/−102, −107/−104, and −227/−224) on the DBH proximal promoter. The deletion and mutagenesis experiments indicate that the motif at −227/−224 is required for Egr1-elicited reduction in DBH promoter activity. It remains to be determined

• These studies established IAP proteins as dimeric RING E lig

  2019-07-13

  

  These studies established IAP proteins as dimeric RING E3 ligases, but did not account for the essential role of dimerization. In IAPs and related E3s, such as RNF4 and MDM2, dimerization not only depends on contacts from the core RING domain but also residues N- and C-terminal to the RING domain (B

16245 records 1013/1083 page Previous Next First page 上5页 10111012101310141015 下5页 Last page